CompletedPhase 2NCT03895801
Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis.
Studying Granulomatosis with polyangiitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- InflaRx GmbH
- Principal Investigator
- Anja Pfaff, PhD, NPCInflaRx GmbH
- Intervention
- IFX-1(drug)
- Enrollment
- 57 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2021
Study locations (30)
- Clinical Site, Leuven, Belgium
- Clinical Site, Liège, Belgium
- Clinical Site, Hradec Králové, Czechia
- Clinical Site, Prague, Czechia
- Clinical Site, Angers, France
- Clinical Site, Brest, France
- Clinical Site, Créteil, France
- Clinical Site, Grenoble, France
- Clinical Site, Lille, France
- Clinical Site, Montpellier, France
- Clinical Site, Paris, France
- Clinical Site, Pessac, France
- Clinical Site, Poitiers, France
- Clinical Site, Jena, Thuringia, Germany
- Clinical Site, Aachen, Germany
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03895801 on ClinicalTrials.govOther trials for Granulomatosis with polyangiitis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06940661Obinutuzumab for Remission Induction in Patients With Relapsing PR3-ANCA Granulomatosis With PolyangiitisAssistance Publique - Hôpitaux de Paris
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT03919435TEMPO Study: Trimethoprim-Sulfamethoxazole in Granulomatosis With PolyangiitisUniversity of Pennsylvania
- ACTIVE NOT RECRUITINGPHASE3NCT01933724The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric ApproachUniversity of South Florida